Inhibikase Therapeutics Achieves Major Milestone: Enrollment of First Patient in Global Phase 3 Study for Pulmonary Arterial Hypertension (PAH)

Key Highlights for Investors

• First patient enrolled in pivotal Phase 3 IMPROVE-PAH study of IKT-001, a novel therapy for PAH.
• IMPROVE-PAH is a single, adaptive, global Phase 3 study designed to accelerate potential NDA submission.
• Innovative oral prodrug IKT-001 aims to reduce gastrointestinal side effects commonly seen with existing imatinib therapies, potentially improving patient tolerability and compliance.
• FDA has provided written confirmation supporting the adaptive study design and 12-week dose-titration phase.
• Study expected to enroll patients at up to 180 sites worldwide, underscoring significant scale and potential market impact.
• IMPROVE-PAH’s primary endpoints target both hemodynamic (Pulmonary Vascular Resistance at 24 weeks) and functional (6-minute walk distance at 24 weeks) outcomes, with built-in flexibility for sample size adjustment based on interim data.
• Positive expert commentary from leading PAH clinicians highlights the potential of IKT-001 as a novel antiproliferative therapy in an area of high unmet need.

Detailed Overview

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced a significant clinical milestone with the enrollment of the first patient in its global, pivotal Phase 3 IMPROVE-PAH trial investigating IKT-001 for the treatment of Pulmonary Arterial Hypertension (PAH). This event marks a culmination of months of strategic planning and protocol optimization to enable a single, adaptive global study, which could notably accelerate the company’s timeline toward filing a New Drug Application (NDA).

IKT-001 is a novel oral prodrug of imatinib mesylate, engineered to minimize gastrointestinal side effects—a key limitation of standard imatinib therapy. The company has leveraged over 20 years of clinical experience with imatinib, alongside the anticipated GI benefits of IKT-001, to design what it believes is a high-probability, high-impact clinical program.

IMPROVE-PAH Study Design

The IMPROVE-PAH trial employs a two-part adaptive Phase 3 design:

• Part A: Double-blind, placebo-controlled trial in approximately 140 patients, measuring change in Pulmonary Vascular Resistance (PVR) at Week 24.
• Part B: Seamless continuation after Part A, with identical design, but focusing on change in 6-minute walk distance (6MWD) at Week 24 in approximately 346 patients.

Notably, the protocol includes a 12-week dose-titration phase to achieve the highest tolerable dose for each patient, as well as a flexible sample size re-estimation for Part B based on interim findings.

The trial will be conducted at up to 180 sites globally, positioning it as one of the largest and most comprehensive studies in PAH to date. This scale and scope could significantly enhance visibility, data robustness, and regulatory confidence.

Expert Validation

Leading PAH clinicians, including Dr. Harrison Farber of Tufts Medical Center and Dr. J. Wesley McConnell of Norton Pulmonary Specialists, have voiced strong support for the study. They cite the urgent need for new therapies with antiproliferative mechanisms and the trial’s focus on clinically meaningful endpoints, such as exercise capacity, hemodynamics, and time to clinical worsening. Both experts underscore the potential for IKT-001 to address persistent disease progression in PAH, despite current therapies.

About Inhibikase Therapeutics

Inhibikase is a clinical-stage biotech company focused on modifying the course of cardiopulmonary diseases via inhibition of type III receptor tyrosine kinases, including PDGF receptors and c-Kit. Its lead candidate, IKT-001, is a prodrug of imatinib for the orphan indication of PAH—a progressive, life-threatening disorder impacting approximately 50,000 Americans. Imatinib itself has a long-established safety profile in oncology and hematology, with first reports of PAH use dating to 2005.

The IMPROVE-PAH study is the company’s pivotal Phase 3 trial, actively enrolling at an anticipated 180 sites worldwide.

Potential Price-Sensitive Information for Shareholders

• First patient enrollment in a pivotal, potentially registrational Phase 3 trial represents a major value-creation milestone.
• Study design, supported by the FDA, may accelerate regulatory timelines and reduce development risk.
• The scale of the trial and global reach underscores strong execution and market potential, factors that could impact valuation and investor sentiment.
• Positive feedback from leading PAH experts increases credibility and potential for clinical and commercial success.
• If successful, IKT-001 could become a first-in-class antiproliferative therapy for PAH with a differentiated safety profile, addressing a high unmet need and expanding Inhibikase’s addressable market.

Forward-Looking Statements

This article contains forward-looking information based on the company’s current plans and expectations, including clinical trial design, regulatory pathways, and the potential impact of IKT-001 in PAH. Actual results may differ materially due to risks related to clinical development, regulatory review, operational execution, and other factors as disclosed in Inhibikase’s SEC filings.

Contact Information

Investor Relations:
Michael Moyer, LifeSci Advisors
[email protected]

Disclaimer

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making investment decisions. The information provided is based on company disclosures and may be subject to change. No responsibility is accepted for any losses arising from reliance on this information.

View Inhibikase Therapeutics, Inc. Historical chart here